Show results for
Refine by
Clinical Program Equipment & Supplies In Japan
35 equipment items found
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ ...
Manufactured by:Aposcience AG based inVienna, AUSTRIA
Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled ...
Manufactured by:Elixir Medical Corporation based inMilpitas, CALIFORNIA (USA)
Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications: Drug-eluting stents, Transplant, Oncology. Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, ...
by:Align Technology, Inc. based inTempe, ARIZONA (USA)
The Invisalign system is the most advanced clear aligner system in the world. Backed by two decades of innovation, the Invisalign system has helped bring smiles to over 9.6 million people including over 2.4 million ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor. More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research. ...
Manufactured by:Ito Co., Ltd. based inKawaguchi City, Saitama, JAPAN
Electrotherapy Device with 2 Independent Channels and Body Diagram ...
Manufactured by:Ito Co., Ltd. based inKawaguchi City, Saitama, JAPAN
Electrotherapy Device with 4 Independent Channels and Body Diagram ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US) is an oromucosal spray of a formulated cannabis extract that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD), as well as specific minor cannabinoids and other non-cannabinoid components. We developed Sativex® to be administered as an oromucosal spray, ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Many of the childhood-onset intractable epilepsy conditions within the expanded access program share considerable overlap with ASD and these conditions often fall within the orphan disease space. Initial clinical observations from treating physicians suggest a potential role for cannabinoids in addressing problems associated with ASD such as deficits in ...
Manufactured by:Elixir Medical Corporation based inMilpitas, CALIFORNIA (USA)
Novolimus is a metabolite of the drug Sirolimus, a novel mTOR inhibitor macrolytic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir Medical. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy ...
by:Relmada Therapeutics, Inc. based inCoral Gables, FLORIDA (USA)
Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). REL-1017 works with a MOA markedly different from standard serotoninergic ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of cancer death. The clinical candidate is a first-in-class, GPC3-FcA-LNP, with a strong preclinical profile supporting its advance into this ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
GW is committed to developing new medicines to treat rare, treatment-resistant epilepsy conditions where there are limited or in some cases, no approved treatment ...
Manufactured by:Ito Co., Ltd. based inKawaguchi City, Saitama, JAPAN
High-end Combination Unit with 3 Independent Channels and Body Diagram ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-109 is a first-in-class investigational microbiome therapeutic administered orally following antibiotics to reduce recurrence of C. difficile infection (CDI) in patients with recurrent ...
Manufactured by:Ito Co., Ltd. based inKawaguchi City, Saitama, JAPAN
High-end Combination Unit with 5 Independent Channels and Body Diagram ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-301 is an investigational, oral, rationally-designed, fermented microbiome therapeutic for the treatment of mild-to-moderate ulcerative colitis (UC). SER-301 is a consortium of multiple bacterial strains that is manufactured by fermenting each strain individually and then combining to form drug product. ...